The Old-School 1960s NASA Space Food That Landed In American Pantries
Space Food Sticks were among the first foods engineered specifically for space conditions: crumb-free, shelf-stable, and packed with essential nutrients. It's unclear if all versions of Pillsbury Space Food Sticks had the same basic contents. However, some ingredient lists reveal a mix of soy and milk proteins, glucose, sugar, vegetable fats and emulsifiers. The available flavors of chocolate and peanut butter were all-American, but they offered kids a taste of outer space with no rocket required. Chocolate itself had already made its way into orbit in the early 1960s. Yuri Gagarin became the first astronaut who brought it into space, proving that even sweet treats could make the journey. The popularity of these snacks reflected the nation's obsession with astronauts and exploration, placing them alongside a wave of other space-inspired food experiments. Even iconic brands jumped into orbit, like Coca-Cola, which produced the first soda to go to space after an ambitious mission to prove soft drinks could be enjoyed in zero gravity.
Read more: Canned Ham Brands Ranked From Worst To Best
From Orbit To The Snack Aisle
As Space Food Sticks faded into the darkness of space exploration lore, novelty snacks like freeze-dried ice cream and strawberries captured the public imagination, even if they rarely flew in spacecraft. First introduced to museum gift shops in the mid-1970s, the crunchy Neapolitan treat was created for the NASA Apollo 7 mission. However, it's not clear if the product was actually used in that capacity. Smithsonian space history curator Jennifer Levasseur explained that the astronauts might have had "a chance to try it out before the mission to see if they liked it." Her own experience tasting the chalky snack led her to claim it was "like eating foam." Despite never actually becoming standard astronaut fare (the International Space Station received freezers for real ice cream in 2006), it has cemented its place in pop culture. It continues to sell in the gift shops of places like the Kennedy Space Center, even decades later.
The fascination with space-themed eats may have started with food sticks, but didn't end with ice cream. Even today, NASA continues to experiment with food and snacks designed for actual missions, like this seven-ingredient space salad — full of nutrients and free of dressing that they hope to one day grow entirely in orbit. Space food may have evolved since we first landed on the moon, but its legacy still fuels curiosity and snack cravings across the galaxy.
Read the original article on Mashed.
Solve the daily Crossword
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Gizmodo
an hour ago
- Gizmodo
‘Alien: Earth' Star Alex Lawther on That Very Sci-Fi Sibling Reunion
Alien: Earth has finally arrived, bringing weekly doses of Ridley Scott's world of Alien—filtered through the creative lens of Noah Hawley—to sci-fi fans. The first two episodes (read io9's recap here) had to spend a bit of time doing necessary setup, introducing the characters and how they fit into the story that'll unfold. So far one of the most unique relationships is the one between Joe, aka Hermit (Alex Lawther) and Wendy (Sydney Chandler), formerly Marcy. They're siblings, with a the episodes explore, Marcy (a very sick child) becomes Wendy (a synthetic body with a human consciousness), but her soldier brother, Hermit, isn't aware that's happened. When the two meet—amid a lot of alien-adjacent chaos, naturally—he has to grapple with the revelation that not only is his sister still alive, but she's also become a hybrid person. It's a lot to take in, and speaking to Collider, Lawther—who Star Wars fans will recognize from Andor—described how he approached all those emotions in his performance. 'It's a moment of horror, I kept on thinking … This person who you thought you'd lost has been found. There's a deeply unsettling uncanniness to that. And I think for the first takes of it, I was just sort of like—and [episode two director Dana Gonzalez] was like, 'Maybe turn it down,' because I just felt sort of freaked out by the whole situation,' Lawther said. 'I found it more viscerally frightening than being faced with the Xenomorph, was being faced by a dead sibling come back to life. She's essentially a ghost to him, and also, she's in this other body. Can you imagine? Like a zombie, this other body opening its mouth and saying, 'Hey, man, it's me. I'm your dead sister. I'm alive, but I'm in a different body.'' Much like the film franchise that spawned it, not all the horror in Alien: Earth will involve aliens, it seems. However, if you've seen the first two episodes, you know there's also plenty of oozy extraterrestrial terror on the show too. Have you checked it out yet? Want more io9 news? Check out when to expect the latest Marvel, Star Wars, and Star Trek releases, what's next for the DC Universe on film and TV, and everything you need to know about the future of Doctor Who.
Forbes
an hour ago
- Forbes
STEM Toys: Higher Education Becomes Child's Play
Growing up in mid-century America school was about work, often drudgery. Play happened on playgrounds except for those of us 'visiting' the principal's office. Today, with the advent of STEM learning, play found its way into classrooms and after class clubs. STEM (Science, Technology, Engineering, Mathematics) and STEAM (adding Arts) has a rich and fascinating history that reflects shifts in education, technology, and cultural values, and traces back to the Morrill Act of 1862. The STEM movement gained thrust in the 1950's with the advent of the 'space race' and inauguration of the National Aeronautics and Space Administration (NASA) in 1958. The scientific achievements of the next three decades from the moon landing, the artificial heart, personal computing, and cell phones all yielded a call for enhanced science education. From SMET to STEM to STEAM The call was answered by the National Science Foundation (NSF) which established guidelines for the teaching of science, math, engineering, and technology in grades K-12, introducing the acronym SMET. However, educators and policymakers found the term awkward and unappealing — even suggesting it sounded like 'smut.' So, in 2001 the NSF officially rebranded the initiative STEM, and more recently STEAM, as 'Art' was added. The early twentieth century spawned three iconic toys promoting interest in engineering including the Erector Set (1913), Tinker Toys (1914), and Lincoln Logs (1916). The latter, invented by John Lloyd Wright, son of the architect Frank Lloyd Wright, were among the first toys to be marketed to both boys and girls selling over one hundred million sets worldwide. By the 1950's plastics began to populate the toy chest expanding access to educational play, aka 'edutainment.' This was brought home, both literally and figuratively, when my captivation over my first haircut led my father to a failed search for a toy-like barbershop kit. This set the stage for midwestern entrepreneurs and twin-brothers Al and Lou Stein (my father and uncle) to file patent and trademark application for 'Hippity Hop Barber Shop,' a life-like six-piece plastic barber shop play kit. In 1951, Hippity Hop debuted at the New York Toy Fair and was featured as an 'Educational Toy for Children from Two to Twelve.' The red-white-and blue packaging boasted the toy's 'Durable, Pliable, Acetate Plastic' while stating 'HARMLESS…WILL NOT CUT HAIR.' In 1958, a relatively unknown maker of wooden toys from the town of Billund, Denmark patented and introduced modular plastic building blocks inspiring problem solving through construction. Now, 1.1 trillion 'bricks' later, LEGO is considered the most valuable toy brand on the planet while also becoming the leading STEAM product producer. It is estimated that between 20-30 percent of LEGO's over $10 billion annual sales comes from educational products widely used in classrooms, competitions, and home learning. STEAM kits began making their way into K–12 classrooms in the early 2000's. But their widespread adoption accelerated around 2010–2015, driven by federal initiatives like Educate to Innovate (2009) and 'Race to the Top' which encouraged schools to invest in STEAM resources. Besides LEGO, companies like Sphero and Thames & Kosmos began tailoring products for classroom use. Next, makerspaces and project-based learning gained traction bringing STEAM toys into elementary schools. In 2024 the market size for STEAM toys and kits was estimated to be $6 billion and is expected to more than double in a decade. The drivers behind this growth include smart STEAM kits using AI and machine learning, subscription models, and online retail. With continued STEAM market maturation, category segmentation, and broad user age range it is difficult to predict which brands will become tomorrow's leaders or laggards. That said, here's an overview of the key product categories along with STEAM sector standouts: Besides the major players, STEAM toys, kits, and teaching methodologies have spawned countless smaller niche manufacturers worldwide. Yet, 70 to 80 percent of the world's toys are still being manufactured in China, as China's infrastructure and expertise make it the go-to hub for toy manufacturing. Within China's Guangdong Province, Shenzhen is known as the 'maker's dream city' housing over 5,000 toy factories — the largest such concentration in China. The city specializes in electronic toys, STEAM kits, plush toys, and custom collectibles, serving both domestic and global markets. Some began as 'cottage industries' in homes selling to schools and school systems before gaining traction and developing wholesale distribution. I was recently introduced to one such Shenzhen based STEAM kit brand, ACEBOTT, which has a particularly fascinating backstory and one I found somewhat reminiscent of my own family's 'Hippity Hop' gambit, albeit from a more principled origin. The journey into STEAM education for ACEBOTT founder and CEO Ring Huang began with deep personal motivation. As both a mother and an educator Ring Huang was frustrated by the lack of engaging, accessible tools to instruct her students about coding and technology. That frustration sparked a mission: to create hands-on kits that would make learning STEAM fun, intuitive, and empowering for kids everywhere. Ring Huang launched ACEBOTT in 2013 with a vision of helping young learners explore the 'Code Forest'—a metaphor for the vast adventurous world of coding and innovation. Under her leadership, ACEBOTT has grown into a global brand with strong presence in classrooms, maker spaces, and homes around the world. ACEBOTT tout's a curriculum-first approach, supported by the fact that their R&D team is comprised of engineers with strong STEAM education backgrounds. Ring Haung states 'We design products from a teacher's perspective, building around what students need to learn, not just what's fun to build.' ACEBOTT offers three distinct product lines each targeting a specific audience: Their curriculum-focused education series offers a 6-year progressive STEAM system designed to align with real-world applications such as Smart Home, Transportation, and Factory, making it easy for schools to adopt. I found ACEBOTT's eco-friendly wooden materials used in their STEAM kits to be a refreshing brand differentiator. This is depicted in an online case study of a German elementary school using ACECode Blockly to explore key smart home systems in a beginner-friendly visual programming platform. ACEBOTT has a growing client base in Europe and is continuing to expand globally. STEAM brands and products are being sourced online, in big boxes stores like Walmart and Target, and through a vast network of specialty toy stores, worldwide. However, it's my belief that independent specialty toy retailers are particularly well suited to prosper in the category given their emphasis on customer service and devotion to staff training. And ASTRA can become their North Star. The American Specialty Toy Retailing Association (ASTRA) focuses on independent toy retailers and specialty manufacturers and promotes creative play and educational toys. It also offers networking, trade shows, and advocacy. Additionally, Women in Toys, Licensing & Entertainment (WIT) supports women across the toy, licensing, and entertainment industries and offers mentorship, leadership development, and industry recognition. Additionally, The Toy Association, founded in 1916 as the Toy Manufacturers of America, Inc., publishes detailed reports like 'Decoding STEAM' to help manufacturers, educators, and parents understand and promote STEAM learning through play. This makes The Toy Association not just a general industry body, but a strategic ally for companies like ACEBOTT that are deeply invested in educational impact and hands-on learning.
Yahoo
an hour ago
- Yahoo
ImmunityBio Reports Complete Responses in Non-Hodgkin Waldenstrom Lymphoma Patients with Chemotherapy-Free, First-In-Class CD19 CAR-NK Immunotherapy
Single-agent CD19 CAR-NK cell therapy achieved a complete response in third-line Waldenstrom macroglobulinemia (WM), a type of non-Hodgkin lymphoma Second patient maintains an ongoing complete response at six months with CD19 CAR-NK in combination with rituximab and a third WM patient has been enrolled in the study First study to demonstrate the potential for complete responses with a chemotherapy-free immunotherapy in late-stage WM patients validating the power of NK cells CULVER CITY, Calif., August 13, 2025--(BUSINESS WIRE)--ImmunityBio (NASDAQ: IBRX), a leading immunotherapy company, announced today early findings from its QUILT-106 Phase I trial, showing highly promising complete responses in the first two patients treated to date with late-stage Waldenstrom macroglobulinemia (WM)—a type of non-Hodgkins lymphoma (NHL)—using its CD19 CAR-NK (CD19 t-haNK) natural killer cell therapy. QUILT-106 (NCT06334991) is a first-in-human trial evaluating the safety and preliminary efficacy of CD19 CAR-NK cell therapy alone and in combination with rituximab in patients with relapsed or refractory (R/R) CD19⁺CD20⁺ B-cell NHL. The disease remains challenging to treat, and WM is considered incurable with existing treatment options, making novel immunotherapies an important avenue of exploration for potential effective treatments. In the first two evaluable patients with WM who were heavily pretreated, an entirely chemotherapy-free, immunotherapy regimen induced encouraging responses. Both patients tolerated the regimen with no significant toxicities. Notably, all infusions (including CAR-NK cells and cytokines) were administered in an outpatient setting. One patient achieved a complete response (CR) with CD19 CAR NK monotherapy, while the second patient achieved CR with CD19 CAR-NK in combination with rituximab. Remission was maintained and is ongoing for six months to date. The open-label study sponsored by ImmunityBio and led by Dr. Glenda Gray, former President and CEO of the South African Medical Research Council (SAMRC) and current Chair of the Global Antibiotic Research and Development Partnership (GARDP), has enrolled 13 patients with NHL at three sites in South Africa. Of the patients enrolled so far, three have WM. Eligible study participants express CD19 and CD20, with active disease after ≥2 chemotherapy-based lines of treatment. All patients receive a lead-in cycle of CD19 CAR-NK cell monotherapy, followed by a 1-week safety observation pause, then a second cycle combining CD19 CAR-NK with rituximab. Key endpoints include safety/tolerability and objective response rate (ORR) by standard criteria. "The preliminary findings we have submitted for presentation at the American Society of Hematology annual meeting provides the first evidence that novel immunotherapy combinations without chemotherapy lymphodepletion can provide deep and durable remissions in WM even after multiple prior treatments," said Dr. Jackie Thomson, Wits University Donald Gordan Medical Center, Johannesburg, South Africa and the lead author of the paper. "Recruitment in this rare subset of lymphoma is ongoing to confirm these findings and to establish this chemo-free strategy as a viable treatment option for relapsed WM." ImmunityBio's CD19 CAR-NK Therapy CD19 CAR-NK is a targeted high-affinity natural killer cell therapy – an off-the-shelf, allogeneic NK cell line engineered to express a CD19-specific chimeric antigen receptor (CAR) and a high-affinity CD16 (FcγRIIIa 158V) receptor. This design enables dual anti-tumor mechanisms: direct CAR-mediated cytotoxicity and augmented antibody-dependent cellular cytotoxicity when paired with anti-CD20 monoclonal antibody rituximab. Combining CD19 CAR-NK cells with rituximab could thereby target CD19⁺/CD20⁺ lymphoma cells to enhance tumor cell killing. About ImmunityBio ImmunityBio is a vertically-integrated commercial stage biotechnology company developing next-generation therapies that bolster the natural immune system to defeat cancers and infectious diseases. The Company's range of immunotherapy and cell therapy platforms, alone and together, act to drive and sustain an immune response with the goal of creating durable and safe protection against disease. Designated an FDA Breakthrough Therapy, ANKTIVA is the first FDA-approved immunotherapy for non-muscle invasive bladder cancer CIS that activates NK cells, T cells, and memory T cells for a long-duration response. The Company is applying its science and platforms to treating cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies that we believe sharply reduce or eliminate the need for standard high-dose chemotherapy. These platforms and their associated product candidates are designed to be more effective, accessible, and easily administered than current standards of care in oncology and infectious diseases. For more information, visit (Founder's Vision) and connect with us on X (Twitter), Facebook, LinkedIn, and Instagram. Forward Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements regarding potential implications to be drawn from preliminary clinical study results, clinical trial enrollment, timing, data and potential results to be drawn therefrom, anticipated components of ImmunityBio's CancerBioShield™ platform, the development of therapeutics for cancer and infectious diseases, potential benefits to patients, potential treatment outcomes for patients, the described mechanism of action and results and contributions therefrom, potential future uses and applications of ANKTIVA alone or in combination with other therapeutic agents across multiple tumor types and indications and for potential applications beyond oncology, potential regulatory pathways and the regulatory review process and timing thereof, the application of the Company's science and platforms to treat cancers or develop cancer vaccines, immunotherapies and cell therapies that have the potential to change the paradigm in cancer care, and ImmunityBio's approved product and investigational agents as compared to existing treatment options, among others. Statements in this press release that are not statements of historical fact are considered forward-looking statements, which are usually identified by the use of words such as "anticipates," "believes," "continues," "goal," "could," "estimates," "scheduled," "expects," "intends," "may," "plans," "potential," "predicts," "indicate," "projects," "is," "seeks," "should," "will," "strategy," and variations of such words or similar expressions. Statements of past performance, efforts, or results of our preclinical and clinical trials, about which inferences or assumptions may be made, can also be forward-looking statements and are not indicative of future performance or results. Forward-looking statements are neither forecasts, promises nor guarantees, and are based on the current beliefs of ImmunityBio's management as well as assumptions made by and information currently available to ImmunityBio. Such information may be limited or incomplete, and ImmunityBio's statements should not be read to indicate that it has conducted a thorough inquiry into, or review of, all potentially available relevant information. Such statements reflect the current views of ImmunityBio with respect to future events and are subject to known and unknown risks, including business, regulatory, economic and competitive risks, uncertainties, contingencies and assumptions about ImmunityBio, including, without limitation, (i) risks and uncertainties regarding participation and enrollment and potential results from the clinical trial described herein, (ii) whether clinical trials will result in registrational pathways, (iii) whether clinical trial data will be accepted by regulatory agencies, (iv) the ability of ImmunityBio to fund its ongoing and anticipated clinical trials, (v) the ability of ImmunityBio to continue its planned preclinical and clinical development of its development programs through itself and/or its investigators, and the timing and success of any such continued preclinical and clinical development, patient enrollment and planned regulatory submissions, (vi) potential delays in product availability and regulatory approvals, (vii) ImmunityBio's ability to retain and hire key personnel, (viii) ImmunityBio's ability to obtain additional financing to fund its operations and complete the development and commercialization of its various product candidates, (ix) potential product shortages or manufacturing disruptions that may impact the availability and timing of product, (x) ImmunityBio's ability to successfully commercialize its approved product and product candidates, (xi) ImmunityBio's ability to scale its manufacturing and commercial supply operations for its approved product and future approved products, and (xii) ImmunityBio's ability to obtain, maintain, protect, and enforce patent protection and other proprietary rights for its product candidates and technologies. More details about these and other risks that may impact ImmunityBio's business are described under the heading "Risk Factors" in the Company's Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on March 3, 2025, and the Company's Form 10-Q filed with the SEC on August 5, 2025, and in subsequent filings made by ImmunityBio with the SEC, which are available on the SEC's website at ImmunityBio cautions you not to place undue reliance on any forward looking statements, which speak only as of the date hereof. ImmunityBio does not undertake any duty to update any forward-looking statement or other information in this press release, except to the extent required by law. View source version on Contacts InvestorsHemanth Ramaprakash, PhD, MBA ImmunityBio, Inc. +1 MediaSarah Singleton ImmunityBio, Inc. +1 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
